Polycystic Ovary Versus Polycystic Ovary Syndrome
Published 2008 · Medicine
Download PDFAnalyze on Scholarcy
The polycystic ovary syndrome (PCOS) is a heterogeneous condition. Polycystic ovaries are detected in 19–33% of the “general population,” of whom approximately 80% have symptoms of PCOS, albeit for many such symptoms are usually mild. Thus, about 20% of women with polycystic ovaries are symptom free. It appears that ovarian dysfunction is expressed when the ovaries of women with polycystic ovaries alone are stressed, by either a gain in weight, a rise in circulating insulin levels, or stimulation with follicle-stimulating hormone (FSH) for assisted conception treatments. Longitudinal studies are required to better explore the evolution of signs and symptoms of the syndrome over time in women with polycystic ovaries and by comparison with those with normal ovaries.
This paper references
Gonadotrophin and gonadal steroid response to a single dose of a long‐acting agonist of gonadotrophin‐releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome
D. White (1995)
In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome.
R. Homburg (1993)
POLYCYSTIC OVARY SYNDROME: A CHANGING PERSPECTIVE
S. Franks (1989)
Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy
J. I. Isojärvi (1993)
Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility.
A. Mulders (2004)
Hypogonadotropic patients with ultrasonographically detected polycystic ovaries: endocrine response to pulsatile gonadotropin-releasing hormone.
M. Schachter (1996)
Hyperinsulinaemia in the polycystic ovary syndrome confirmed with a specific immunoradiometric assay for insulin
G. Conway (1993)
Hypersecretion of androgens by polycystic ovaries: the role of genetic factors in the regulation of cytochrome P450c17 alpha.
S. Franks (1996)
A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization.
M. Macdougall (1993)
Assisted reproductive technologyComparison of natural with clomiphene citrate-stimulated cycles in in vitro fertilization: a prospective, randomized trial*
Margaret Jane MacDougall (1994)
Polycystic ovary syndrome.
S. Franks (1997)
Sonographic incidence of polycystic ovaries in a gynecological population.
D. Botsis (1995)
Fetal growth, length of gestation, and polycystic ovaries in adult life
J. Cresswell (1997)
Dysregulation of cytochrome P450c17α as the cause of polycystic ovarian syndrome
Robert L. Rosenfield (1991)
How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?
R. Clayton (1992)
Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid.
H. Mason (1994)
Polycystic ovarian disease
J. Goldzieher (1981)
Comparison of natural with clomiphene citrate-stimulated cycles in in vitro fertilization: a prospective, randomized trial.
M. Macdougall (1994)
Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization.
J. Smitz (1990)
Granulosa cells of polycystic ovaries: are they normal or abnormal?
G. Erickson (1992)
Polycystic ovaries and associated clinical and biochemical features in young women
K. F. Michelmore (1999)
Formation and early development of follicles in the polycystic ovary
LJ Webber (2003)
Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.
A. Dunaif (1997)
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).
B. Fauser (2004)
Ultrasound appearance of the ovaries during the pill-free interval.
Y. Tayob (1990)
Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients.
A. Balen (1994)
Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women.
A. Clark (1995)
POLYCYSTIC OVARIES—A COMMON FINDING IN NORMAL WOMEN
D. Polson (1988)
Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
R. Barnes (1989)
Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.
A. Dunaif (1996)
Early ovarian ageing: are women with polycystic ovaries protected?
D. Nikolaou (2004)
Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono‐ovulation
R. Anderson (1998)
Ultrasound assessment of the polycystic ovary: international consensus definitions.
A. Balen (2003)
The treatment of patients with polycystic ovarian syndrome by in-vitro fertilization and embryo transfer: a comparison of results with those of patients with tubal infertility.
J. Dor (1990)
Letter: Kumidini hospital.
Habershon Rb (1975)
Oral contraceptive hazards--1981.
J. Goldzieher (1981)
Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.
A. Balen (1995)
Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin.
C. Bergh (1993)
The Prevalence of Polycystic Ovaries on Ultrasound Scanning in a Population of Randomly Selected Women
C. Farquhar (1994)
This paper is referenced by
Stress-induced activation of ovarian heat shock protein 90 in a rat model of polycystic ovary syndrome
M. H. Jung (2014)
Single nucleotide polymorphisms in treatment of polycystic ovary syndrome: a systematic review
Ritu Deswal (2019)
Stress-induced activation of ovarian heat shock protein 90 in a rat model of polycystic ovary syndrome.
Eunkuk Park (2012)
Obesity, Metabolic Dysfunction, and Inflammation in Polycystic Ovary Syndrome
Mira Aubuchon (2014)